Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

INDUSTRY 42OTHER 41NIH 31NETWORK 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 2

Interventions

Radiotherapy 302Cisplatin 266Cyclophosphamide 230Doxorubicin 177Paclitaxel 170Vincristine 162Carboplatin 152Filgrastim 140Etoposide 139Gemcitabine 118Docetaxel 114Fluorouracil 113Methotrexate 106Dexamethasone 106Cytarabine 106Prednisone 92Leucovorin 90Gene Expression Profiling 82Granulocyte Colony-Stimulating Factor 75Specimen Handling 70Magnetic Resonance Spectroscopy 63Irinotecan 59Capecitabine 59Radiation 54Polymerase Chain Reaction 51Ifosfamide 51Rituximab 49Immunohistochemistry 49Daunorubicin 49Oxaliplatin 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
NETWORK × AZD 6244 × Clear all
NCT02337530 2024-03-21

Selumetinib in Patients Receiving Pemetrexed and Platinum-based Chemotherapy in Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous NSCLC

Canadian Cancer Trials Group

Phase 2 Completed
62 enrolled 13 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01783197 2023-08-04

Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC

Canadian Cancer Trials Group

Phase 1 Completed
39 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡